MR-guided Laser Interstitial Thermal Therapy (MRgLITT) for treatment of epileptogenic zones for Adults with refractory focal epilepsy
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Contract (Services)
- Duration
- not specified
- Value
- £1M-£1M
- Sector
- HEALTH
- Published
- 20 Aug 2024
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
North West England:
1 buyer
- NHS England Leeds
2 suppliers
- Walton Centre NHS Trust Liverpool
- Kings College Hospital NHS Trust London
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England Specialised Commissioning (referred to as the Commissioner), invited suitably qualified and experienced providers to bid for an opportunity to provide MR-guided Laser Interstitial Thermal Therapy (MRgLITT) for treatment of epileptogenic zones for adults with refractory focal epilepsy (Lot 1: North & Lot 2: South). As a result of this procurement exercise the Commissioner has awarded contracts for these services.
Lot Division
| 1 | A. Lot 1- North MRgLITT, also known as ‘laser interstitial thermal therapy’ (LITT), is a minimally invasive treatment which can be used in focal refractory epilepsy. Stereotactic neurosurgical technique is used to guide a 3mm diameter fibreoptic laser to the target area of the brain. Under continuous MRI monitoring, laser energy is applied to the target area to destroy the part of the brain causing seizure activity. It is safer than open neurosurgery as there is less risk of collateral damage to other structures in the brain. Open surgery causes damage along the operative pathway to access the part to be removed, which is mitigated by this minimally invasive approach.The service will commence on 1st September 2024 and will run for a duration of 5 years (initialperiod). The Commissioner has the option to extend for up to a further 2 years making apossible maximum contract duration of 7 years. |
| 2 | B. Lot 2 - South MRgLITT, also known as ‘laser interstitial thermal therapy’ (LITT), is a minimally invasive treatment which can be used in focal refractory epilepsy. Stereotactic neurosurgical technique is used to guide a 3mm diameter fibreoptic laser to the target area of the brain. Under continuous MRI monitoring, laser energy is applied to the target area to destroy the part of the brain causing seizure activity. It is safer than open neurosurgery as there is less risk of collateral damage to other structures in the brain. Open surgery causes damage along the operative pathway to access the part to be removed, which is mitigated by this minimally invasive approach.The service commenced on 23rd July 2024 and will run for a duration of 5 years (initialperiod). The Commissioner has the option to extend for up to a further 2 years making apossible maximum contract duration of 7 years. |
Award Detail
| 1 | Walton Centre NHS Trust (Liverpool)
|
| 2 | Kings College Hospital NHS Trust (London)
|
Award Criteria
| Quality (Service Delivery / Technical) | 90% |
| Social Value | 10% |
| N/A | 0% |
CPV Codes
- 85100000 - Health services
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** Link to Clinical Commissioning Policy:https://www.england.nhs.uk/wp-content/uploads/2022/10/2006-Clinical-commissioning-policy-MR-guided-laser-interstitial-thermal-therapy-for-treatment-of-epileptogenic.pdfThe procurement was advertised and conducted in accordance with the requirements of the Public Contracts Regulations 2015 (as amended) (the “Regulations”) to the extent that the Regulations relate to services within the scope of Schedule 3 thereto (Social and Other Specific Services). The Commissioner and AGCSU are, therefore, bound only by those parts of the Regulations applying to Schedule 3 services.
Reference
- ocds-h6vhtk-03f036
- FTS 026376-2024